High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes

American Journal of Clinical Pathology

Volumn 139, Issue 3, 2013, Pages 380-387

  Gianelli, Umberto ^a   Fracchiolla, Nicola S ^b   Bucciarelli, Paolo ^c   Ferla, Valeria ^b   Boiocchi, Leonardo ^a   Savi, Federica ^a   Moro, Alessia ^d   Reda, Gianluigi ^b   Bosari, Silvano ^a   Cortelezzi, Agostino ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

Author keywords

International Prognostic Scoring System; Myelodysplastic syndrome; Prognosis; Vascular endothelial growth factor; WHO classification based prognostic scoring system

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN RETRIEVAL; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LEUKEMIA FREE SURVIVAL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; BIOSYNTHESIS; BONE MARROW CELL; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; BONE MARROW CELLS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84875893975     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP5O3YBKTGGWNQ     Document Type: Article

References (25)

1. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464-478.
2. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
3. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. Blood. 2005;105:1383-1395.
4. Weigand M, Hantel P, Kreienberg R, et al. Autocrine vascular endothelial growth factor signalling in breast cancer: Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis. 2005;8:197-204.
5. Price DJ, Miralem T, Jiang S, et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001;12:129-135.
6. Lee TH, Seng S, Sekine M, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/flt1. PLoS Med. 2007;4:e186.
7. von Marschall Z, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology. 2000;119:1358-1372.
8. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-958.
9. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl). 2003;81:20-31.
10. Xue Y, Chen F, Zhang D, et al. Tumor-derived VRGF modulates hematopoiesis. J Angiogenes Res. 2009;1:9.
11. Vincent L, Jin DK, Karajannis MA, et al. Fetal stromaldependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Res. 2005;65:3185-3192.
12. Wang ES, Teruya-Feldstein J, Wu Y, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood. 2004;104:2893-2902.
13. Boiocchi L, Vener C, Savi F, et al. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosomenegative myeloproliferative neoplasms. J Clin Pathol. 2011;64:226-231.
14. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427-1434.
15. Wimazal F, Krauth MT, Vales A, et al. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: Correlation between VEGF expression and the FAB category. Leuk Lymphoma. 2006;47:451-460.
16. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95:1923-1930.
17. Verstovsek S, Estey E, Manshouri T, et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002;118:151-156.
18. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
19. Malcovati L, Germing U, Kuendgen A, et al. Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510.
20. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:87-104.
21. Shaffer LG, Slovak ML, Campbell LJ, eds. ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Basel, Switzerland: S Karger; 2009.
22. Alessandrino EP, Amadori S, Barosi G, et al. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes: A statement from the Italian Society of Hematology. Haematologica. 2002;87:1286-1306.
23. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187-200.
24. Gianelli U, Vener C, Raviele PR, et al. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. Am J Clin Pathol. 2007;128:966-973.
25. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS). Haematologica. 2011;96:1433-1440.